Reuters
20 Jul 2026, 06:01 UTC · 18h ago
Takeda's QDENGA becomes first dengue vaccine approved in India
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Reuters
20 Jul 2026, 06:01 UTC · 18h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
India's drug regulator has approved Takeda Pharmaceutical's dengue vaccine, QDENGA. — Approval in a major market like India provides a significant new revenue stream and expands the addressable patient population for the product.
+0.60QDENGA is the first dengue vaccine to be approved in India. — First-mover advantage creates a competitive moat and allows Takeda to establish market share before other competitors enter.
+0.40Which stocks this story touches
The company received regulatory approval for its dengue vaccine in India, marking a significant market expansion.
Continue reading
6 related stories
Search tags
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Seeking Alpha
5h ago
